Abstract Number: 1335 • 2012 ACR/ARHP Annual Meeting
Remission Induction in Early Active Rheumatoid Arthritis: Comparison of Tocilizumab Versus Methotrexate Monotherapy
Background/Purpose: Tocilizumab (TCZ), as monotherapy and in combination with methotrexate (MTX), has been shown to be efficacious for rheumatoid arthritis patients with insufficient response to…Abstract Number: 1296 • 2012 ACR/ARHP Annual Meeting
An Interim Analysis of the Efficacy of Abatacept in Japanese Biologics-naïve Rheumatoid Arthritis Patients (results from ABROAD study): Comparison of CRP and MMP-3 Level After Treatment with Abatacept Versus Anti-TNF Agents
Background/Purpose: Abatacept (ABA) is a recombinant fusion protein consisting of the extracellular domain of human CTLA-4, binding to CD80/86 on antigen presenting cells (APCs) and…Abstract Number: 1297 • 2012 ACR/ARHP Annual Meeting
Tofacitinib and Adalimumab Achieve Similar Rates of Low Disease Activity in Rheumatoid Arthritis — Lack of Improvement in Disease Activity Score by 3 Months Predicts Low Likelihood of Low Disease Activity At 1 Year
Background/Purpose: Tofacitinib is a novel oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. This post-hoc analysis of the…Abstract Number: 1298 • 2012 ACR/ARHP Annual Meeting
Improvement of Treatment Outcome of Rheumatoid Arthritis with Salazosulfapyridine by Pharmacogenetic Approach
Background/Purpose: Salazosulfapyridine (SASP) is acetylated in liver by N-acetyltransferase2 (NAT2) in the track of metabolism. Previous studies have shown that genotyping of NAT2 is adequate…Abstract Number: 1299 • 2012 ACR/ARHP Annual Meeting
Rituximab Versus Abatacept in Rheumatoid Arthritis Patients with an Inadequate Response to Prior Biologic Therapy: A Retrospective, Single-Center Study
Background/Purpose: Patients with RA who experience an inadequate response to TNF inhibitor (TNFi) therapy (TNF-IR) may be successfully treated using an alternative TNFi or a…Abstract Number: 1300 • 2012 ACR/ARHP Annual Meeting
Characteristics Associated with Biologic Initiation As Monotherapy Versus Combination Therapy in Patients with Rheumatoid Arthritis (RA) in a US Registry Population
Background/Purpose: Approximately one-third of RA patients were prescribed biologic (Bio) monotherapy (MT) i.e. without concomitant disease-modifying anti-rheumatic drugs (DMARD) (Yazici et al., 2008). The purpose…Abstract Number: 1301 • 2012 ACR/ARHP Annual Meeting
Predictors of Significant Disease Activity Score-28 (Using C-reactive protein) Remission Achieved with Intravenous Golimumab in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results of the Phase 3, Multicenter, Double-Blind, Placebo-Controlled Trial
Predictors of Significant Disease Activity Score-28 (Using C-reactive protein) Remission Achieved with Intravenous Golimumab in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results of…Abstract Number: 1302 • 2012 ACR/ARHP Annual Meeting
Early Neutropenia Is Associated with Clinical Response in Patients Receiving Tocilizumab in Rheumatoid Arthritis
Background/Purpose: A reduction in peripheral blood neutrophils count is usually observed with the anti-interleukin (IL) 6 receptor antibody tocilizumab. This often appears few days after…Abstract Number: 1303 • 2012 ACR/ARHP Annual Meeting
Achieving Comprehensive Disease Control in Long-Standing or Early Rheumatoid Arthritis Patients Treated with Adalimumab Plus Methotrexate Versus Methotrexate Alone
Background/Purpose: Effective treatment of rheumatoid arthritis (RA) patients (pts) aims to suppress inflammation, preserve physical function, and prevent structural damage, which together represent the hallmarks…Abstract Number: 1304 • 2012 ACR/ARHP Annual Meeting
Long-Term Use of Adalimumab As Monotherapy Following Attainment of Low Disease Activity with Adalimumab Plus Methotrexate
Background/Purpose: There has been increased interest in understanding whether biologics can be safely withdrawn from patients (pts) receiving combination therapy with MTX once a clinical…Abstract Number: 1305 • 2012 ACR/ARHP Annual Meeting
Three-Year Follow-up of Rituximab in Rheumatoid Arthritis: Results From the Belgian MIRA (MabThera in Rheumatoid Arthritis) Registry
Background/Purpose: The MIRA registry was set up to collect safety, efficacy and (re)treatment practice data for Belgian RA patients treated with rituximab. Methods: All rheumatologists…Abstract Number: 1306 • 2012 ACR/ARHP Annual Meeting
How well Do Patients with Rheumatoid and Psoriatic Arthritis Tolerate Methotrexate? A Retrospective Review of Discontinuation Data From a Large UK Cohort
Background/Purpose: Due to its efficacy and safety, methotrexate (MTX) has become the first-line disease-modifying drug for rheumatoid (RA) and psoriatic arthritis (PsA). Although deemed safe,…Abstract Number: 1307 • 2012 ACR/ARHP Annual Meeting
Anti-IL-6 Receptor Nanobody (ALX-0061) Seamless “First-in-Human” Phase I/II POC Study in Patients with Active RA On Stable MTX Treatment
Background/Purpose: ALX-0061 is a 26kD bispecific IL-6R targeting Nanobody® with monovalent binding to IL-6R and serum albumin. It effectively neutralizes IL-6 pathway activity in-vitro and…Abstract Number: 1308 • 2012 ACR/ARHP Annual Meeting
Opportunistic Infections in Patients with Rheumatoid Arthritis Treated with Rituximab : Data From the Autoimmunity and Rituximab Registry
Background/Purpose: Therapy with biological agents may be associated with opportunistic infections (OIs). Data on the occurrence of OIs in patients with RA treated with rituximab…Abstract Number: 1309 • 2012 ACR/ARHP Annual Meeting
Predictive Risk Factors of Serious Infections in RA Patients Treated with Abatacept in Real Life: Results in the Orencia and Rheumatoid Arthritis (ORA) Registry
Background/Purpose: Little data is available regarding the rate and predicting factors of serious infections in patients with rheumatoid arthritis treated with abatacept (ABA) in daily…